Retatrutide: The Complete 2026 Guide

Retatrutide (LY3437943) is the world's first triple hormone receptor agonist for obesity and type 2 diabetes, simultaneously activating GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it produced the highest weight loss ever recorded in a clinical trial: an average of 24.2% body weight over 48 weeks in Phase 2 (Jastreboff et al., NEJM 2023). This comprehensive guide covers everything known about retatrutide as of 2026, from mechanism of action to clinical data to practical patient information.

Table of Contents

• What Is Retatrutide?
• How Retatrutide Works: Triple Agonism
• Clinical Trial Results
• Dosing and Administration
• Side Effects
• Drug Interactions
• Who Is Eligible
• Cost and Availability
• Retatrutide vs. Other GLP-1 Medications
• Practical Patient Guide
• Frequently Asked Questions

What Is Retatrutide?

Retatrutide is an investigational once-weekly injectable medication developed by Eli Lilly and Company. Its scientific designation is LY3437943. It represents the next evolution in incretin-based therapies: while semaglutide (Ozempic/Wegovy) targets one receptor (GLP-1) and tirzepatide (Mounjaro/Zepbound) targets two (GLP-1 and GIP), retatrutide targets three: GLP-1, GIP, and glucagon receptors simultaneously.

This triple agonist approach produces more weight loss than any previously studied anti-obesity medication, including tirzepatide. The addition of glucagon receptor activation is the key differentiator, adding metabolic benefits that single and dual agonists cannot provide.

Retatrutide is being developed for obesity/overweight, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Phase 3 trials are underway across all three indications.

How Retatrutide Works: Triple Agonism

GLP-1 Receptor Activation

Glucagon-like peptide-1 (GLP-1) receptor activation is the backbone shared with semaglutide and tirzepatide. It suppresses appetite through hypothalamic signaling, slows gastric emptying (food stays in the stomach longer, promoting fullness), stimulates glucose-dependent insulin secretion (lowering blood sugar safely), and reduces food reward signaling in the brain (quieting "food noise"). These effects are responsible for the majority of appetite suppression and a significant portion of the weight loss effect.

GIP Receptor Activation

Glucose-dependent insulinotropic polypeptide (GIP) receptor activation, shared with tirzepatide, enhances insulin sensitivity in fat tissue, may improve beta-cell function (the insulin-producing cells of the pancreas), modulates fat metabolism and distribution, and potentially contributes to appetite regulation through central nervous system GIP receptors. The GIP component may explain why tirzepatide and retatrutide produce more weight loss than pure GLP-1 agonists.

Glucagon Receptor Activation

This is what makes retatrutide unique. Glucagon receptor activation increases energy expenditure through thermogenesis and fat oxidation, promotes hepatic fat oxidation (particularly relevant for fatty liver disease), enhances lipolysis (fat breakdown), may improve amino acid metabolism, and increases basal metabolic rate. The glucagon component is thought to be primarily responsible for retatrutide's superiority over tirzepatide in weight loss outcomes. It also makes retatrutide particularly promising for MASH because it directly addresses liver fat accumulation.

Clinical Trial Results

Phase 2 Trial (Jastreboff et al., NEJM 2023)

The landmark Phase 2 trial enrolled 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. Participants were randomized to various retatrutide doses or placebo for 48 weeks. Results were groundbreaking:

Notably, weight loss curves had not fully plateaued at 48 weeks, suggesting that longer treatment duration could yield even greater results. The 12mg group showed that 93% of participants lost at least 15% of body weight, an unprecedented response rate.

Phase 2 Diabetes Trial

A separate Phase 2 trial in patients with type 2 diabetes showed significant HbA1c reductions (up to 2.0 percentage points), substantial weight loss even in the diabetic population, and improvements in fasting glucose, insulin sensitivity, and lipid profiles.

Phase 3 TRIUMPH Program

The Phase 3 program includes multiple trials (TRIUMPH-1 through TRIUMPH-4) studying retatrutide in obesity, type 2 diabetes, and MASH. Results are expected to support FDA submissions and will provide data on long-term safety, efficacy in diverse populations, cardiovascular outcomes, and liver histology improvements.

Dosing and Administration

Retatrutide is administered as a once-weekly subcutaneous injection. The Phase 2 trial used a dose-escalation schedule starting at 1mg and increasing over 16-20 weeks to the target dose (up to 12mg). Injection is given in the abdomen, thigh, or upper arm. The medication must be refrigerated (36-46 degrees F) and should not be frozen.

For detailed dosing information, see our Retatrutide Dosing Chart.

Side Effects

The most common side effects are gastrointestinal, consistent with the GLP-1 class:

• Nausea: ~26% at 12mg (lower than semaglutide's ~44%)
• Diarrhea: ~22% at 12mg
• Vomiting: ~10-15%
• Constipation: ~10-12%
• Decreased appetite: Common (therapeutic effect)
• Dysesthesia (tingling/burning): Unique to retatrutide, likely from glucagon receptor activation

Most side effects were mild to moderate and occurred during dose escalation. Serious adverse events were rare. For complete side effect information, see our Side Effects Chart.

Drug Interactions

Retatrutide has few direct drug-drug interactions but several important considerations: oral medication absorption may be delayed due to slowed gastric emptying, insulin and sulfonylureas require dose reduction to prevent hypoglycemia, oral contraceptive effectiveness may be reduced, warfarin requires more frequent INR monitoring, and levothyroxine absorption may be affected. For complete information, see our Drug Interactions Reference.

Who Is Eligible

Based on Phase 2 trial criteria and expected FDA indications, likely eligible candidates include adults 18+ with BMI 30+ (obesity) or BMI 27+ with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea). Contraindications include personal or family history of medullary thyroid carcinoma (MTC), MEN2 syndrome, pregnancy or breastfeeding, concurrent use of other GLP-1 receptor agonists, and active pancreatitis.

Cost and Availability

As of April 2026, retatrutide is not yet FDA-approved. It is available through Phase 3 clinical trials and some compounding pharmacies. Brand-name pricing has not been announced but is expected to be comparable to tirzepatide ($1,000-1,500/month without insurance). Compounded versions through telehealth providers like Trimi may offer more affordable access. For updates, see our Cost Tracker and Availability Tracker.

Retatrutide vs. Other GLP-1 Medications

For detailed comparisons, see our Comparison Hub.

Practical Patient Guide

Before Starting

• Discuss all current medications with your provider
• Get baseline labs (metabolic panel, lipids, HbA1c, thyroid, liver function)
• Review contraindications (thyroid cancer history, pregnancy plans)
• Set realistic expectations (results take months, not weeks)

During Treatment

• Prioritize protein intake (1.2-1.6g/kg ideal body weight)
• Stay hydrated (64+ oz daily)
• Engage in resistance training 2-4 times weekly
• Take a daily multivitamin
• Monitor blood pressure, blood sugar (if diabetic), and weight weekly
• Report concerning side effects promptly
• Attend all follow-up appointments

Long-Term Considerations

• Weight maintenance likely requires ongoing treatment
• Medication dose may be adjusted down once target weight is reached
• Lifestyle habits developed during treatment support long-term success
• Regular lab monitoring should continue

Getting Started With GLP-1 Treatment

While retatrutide awaits FDA approval, effective GLP-1 treatment is available now. Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with full medical oversight, including eligibility screening, dose management, side effect support, and ongoing monitoring. Learn how Trimi works.

Frequently Asked Questions

When will retatrutide be FDA approved?

Phase 3 trials are ongoing. If results are positive and the FDA review proceeds normally, approval could come in late 2026 or 2027. Timelines depend on trial completion, data analysis, and regulatory review duration.

Is retatrutide better than Ozempic or Mounjaro?

Phase 2 data shows greater average weight loss with retatrutide (24.2%) compared to semaglutide (15-17%) and comparable or greater than tirzepatide (22-25%). However, Phase 3 data and head-to-head trials are needed for definitive comparison. "Better" also depends on individual response, side effect tolerance, and specific health goals.

Can I get retatrutide now?

Retatrutide is available through clinical trials and some compounding pharmacies. For proven GLP-1 treatment available today, Trimi offers compounded semaglutide and tirzepatide at affordable prices with full medical support.

Is retatrutide safe?

Phase 2 data showed a favorable safety profile with primarily GI side effects that were mostly mild to moderate. Long-term safety data from Phase 3 trials will provide more comprehensive information. The medication carries the standard GLP-1 class warnings including thyroid C-cell tumors (based on rodent data), pancreatitis, and gallbladder disease.

How much does retatrutide cost?

Brand pricing has not been announced. Estimated cost is $1,000-1,500/month without insurance based on tirzepatide pricing. Compounded versions may be available at lower cost through telehealth providers.

Will I regain weight if I stop retatrutide?

Based on data from other GLP-1 medications, weight regain after discontinuation is likely. Most experts view obesity treatment as a chronic, ongoing need, similar to blood pressure or cholesterol management. Maintenance strategies are being studied.